person · Reporting owner

SANDAGE BOBBY W. JR., PHD.

Disclosed activity across 1 company

Tapewire entity: 165548
SEC CIK: 0001046352

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Oncotelic Therapeutics, Inc.MATN · Entity 7822	Director	June 20, 2018	June 22, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Oncotelic Therapeutics, Inc.

Report date June 20, 2018 · Filed June 22, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.22 · Expires 2024-06-20	Direct	258,171	Reported balance After 2018-06-20 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2018-06-20 · Grant · Acquired 258,171 · Balance 258,171 F1: Dr. Sandage was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per shares (the "Stock Options"), in connection with his service as a member of the Board of Directors pursuant to the Amended and Restated Mateon Therapeutics, Inc. 2015 Equity Incentive Plan and the Amended and Restated Non-Employee Director Compensation Policy. F2: The Stock Options will vest in full on June 20, 2019, subject to Dr. Sandage's continued service on the Board of Directors as of such date.

Filing footnotes · ownership attribution and instrument terms

F1: Dr. Sandage was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per shares (the "Stock Options"), in connection with his service as a member of the Board of Directors pursuant to the Amended and Restated Mateon Therapeutics, Inc. 2015 Equity Incentive Plan and the Amended and Restated Non-Employee Director Compensation Policy.

F2: The Stock Options will vest in full on June 20, 2019, subject to Dr. Sandage's continued service on the Board of Directors as of such date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 20, 2018 Filed Jun 22, 2018 20:16 UTC	Oncotelic Therapeutics, Inc. MATN · Entity 7822	GrantStock Option (Right to Buy) · Derivative	258,171	$0.00 Strike: $0.22	$0.00	Disclosure SEC source: 0001209191-18-039183 · doc4.xml · derivative · entry 1 SANDAGE BOBBY W. JR., PHD. · CIK 0001046352 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,171 Underlying: Common Stock · 258,171 shares Expires 2024-06-20 F1 · shares: Dr. Sandage was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per shares (the "Stock Options"), in connection with his service as a member of the Board of Directors pursuant to the Amended and Restated Mateon Therapeutics, Inc. 2015 Equity Incentive Plan and the Amended and Restated Non-Employee Director Compensation Policy. F2 · derivative.exercise_date: The Stock Options will vest in full on June 20, 2019, subject to Dr. Sandage's continued service on the Board of Directors as of such date. Read SEC document
June 09, 2017 Filed Jun 13, 2017 00:30 UTC	Oncotelic Therapeutics, Inc. MATN · Entity 7822	GrantStock Option (Right to Buy) · Derivative	121,483	$0.00 Strike: $0.51	$0.00	Disclosure SEC source: 0001209191-17-039319 · doc4.xml · derivative · entry 1 SANDAGE BOBBY W. JR., PHD. · CIK 0001046352 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,483 Underlying: Common Stock · 121,483 shares Expires 2023-06-09 F1 · shares: Dr. Sandage was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per share (the "Stock Options"), in connection with his service as a member of the Board of Directors pursuant to the Mateon Therapeutics, Inc. 2015 Equity Incentive Plan and the Amended and Restated Non-Employee Director Compensation Policy. F2 · derivative.exercise_date: The Stock Options will vest in full on June 9, 2018, subject to Dr. Sandage's continued service on the Board of Directors as of such date. Read SEC document
October 25, 2016 Filed Oct 27, 2016 20:28 UTC	Oncotelic Therapeutics, Inc. MATN · Entity 7822	GrantStock Option (Right to Buy) · Derivative	135,612	$0.00 Strike: $0.58	$0.00	Disclosure SEC source: 0001209191-16-147151 · doc4.xml · derivative · entry 1 SANDAGE BOBBY W PHD · CIK 0001046352 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,612 Underlying: Common Stock · 135,612 shares Expires 2022-10-25 F1 · shares: Dr. Sandage was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per share (the "Stock Options"), in connection with his appointment to the Board of Directors pursuant to the Mateon Therapeutics, Inc. 2015 Equity Incentive Plan and the Amended and Restated Director Compensation Policy. F2 · derivative.exercise_date: The Stock Options will vest in three equal annual installments on the first, second and third anniversary of the date of grant, subject to Dr. Sandage's continued service on the Board of Directors as of such date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.